Weekly Analysts’ Ratings Changes for CapsoVision (CV)

A number of firms have modified their ratings and price targets on shares of CapsoVision (NASDAQ: CV) recently:

• 12/8/2025 – CapsoVision had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – CapsoVision had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – CapsoVision had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
• 11/20/2025 – CapsoVision had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
• 11/14/2025 – CapsoVision had its “speculative buy” rating reaffirmed by analysts at Benchmark Co..
• 11/5/2025 – CapsoVision was upgraded by analysts at Zacks Research to a “hold” rating.
• 11/4/2025 – CapsoVision was given a new $7.00 price target on by analysts at Roth Capital.
• 11/4/2025 – CapsoVision was upgraded by analysts at Roth Capital to a “strong-buy” rating.

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.